Increased HSF1 expression predicts shorter disease-specific survival of prostate cancer patients following radical prostatectomy.

ABSTRACT: Prostate cancer is a highly heterogeneous disease and the clinical outcome is varying. While current prognostic tools are regarded insufficient, there is a critical need for markers that would aid prognostication and patient risk-stratification. Heat shock transcription factor 1 (HSF1) is crucial for cellular homeostasis, but also a driver of oncogenesis. The clinical relevance of HSF1 in prostate cancer is, however, unknown. Here, we identified HSF1 as a potential biomarker in mRNA expression datasets on prostate cancer. Clinical validation was performed on tissue microarrays from independent cohorts: one constructed from radical prostatectomies from 478 patients with long term follow-up, and another comprising of regionally advanced to distant metastatic samples. Associations with clinic

SUBMITTER: Bjork JK 

PROVIDER: S-EPMC6101287 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature